메뉴 건너뛰기




Volumn 48, Issue 15, 2012, Pages 2293-2299

Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: A clinical experience in 108 patients with metastatic breast cancer

Author keywords

AKT1; Array CGH; Breast cancer; PIK3CA; Targeted therapy

Indexed keywords

AKT1 PROTEIN; ANGIOPOIETIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 4; JANUS KINASE 2; JANUS KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK3CA PROTEIN; PROTEIN KINASE B; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

EID: 84866736379     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.06.014     Document Type: Article
Times cited : (23)

References (24)
  • 1
    • 2342471392 scopus 로고    scopus 로고
    • Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    • T.J. Lynch, D.W. Bell, and R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
    • (2004) N Engl J Med , vol.350 , pp. 2129-2139
    • Lynch, T.J.1    Bell, D.W.2    Sordella, R.3
  • 2
    • 1542503746 scopus 로고    scopus 로고
    • Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1
    • G. Giaccone, R.S. Herbst, and C. Manegold Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1 J Clin Oncol 22 2004 777 784
    • (2004) J Clin Oncol , vol.22 , pp. 777-784
    • Giaccone, G.1    Herbst, R.S.2    Manegold, C.3
  • 3
    • 77954700380 scopus 로고    scopus 로고
    • Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
    • D.W. Miles, A. Chan, and L.Y. Dirix Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer J Clin Oncol 28 2010 3239 3247
    • (2010) J Clin Oncol , vol.28 , pp. 3239-3247
    • Miles, D.W.1    Chan, A.2    Dirix, L.Y.3
  • 4
    • 79953874259 scopus 로고    scopus 로고
    • RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer
    • N.J. Robert, V. Dieras, and J. Glaspy RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer J Clin Oncol 29 2011 1252 1260
    • (2011) J Clin Oncol , vol.29 , pp. 1252-1260
    • Robert, N.J.1    Dieras, V.2    Glaspy, J.3
  • 5
    • 77949503823 scopus 로고    scopus 로고
    • North Central Cancer Treatment Group (NCCTG) N0432: Phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer
    • E.A. Perez, D.W. Hillman, and T. Dentchev North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer Ann Oncol 21 2010 269 274
    • (2010) Ann Oncol , vol.21 , pp. 269-274
    • Perez, E.A.1    Hillman, D.W.2    Dentchev, T.3
  • 6
    • 53749093040 scopus 로고    scopus 로고
    • Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
    • B.P. Schneider, M. Wang, and M. Radovich Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100 J Clin Oncol 26 2008 4672 4678
    • (2008) J Clin Oncol , vol.26 , pp. 4672-4678
    • Schneider, B.P.1    Wang, M.2    Radovich, M.3
  • 7
    • 77955019276 scopus 로고    scopus 로고
    • Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial
    • A. Tutt, M. Robson, and J.E. Garber Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Lancet 376 2010 235 244
    • (2010) Lancet , vol.376 , pp. 235-244
    • Tutt, A.1    Robson, M.2    Garber, J.E.3
  • 8
    • 79953879710 scopus 로고    scopus 로고
    • Biology-driven phase II trials: What is the optimal model for molecular selection?
    • F. Andre, S. Delaloge, and J.C. Soria Biology-driven phase II trials: what is the optimal model for molecular selection? J Clin Oncol 29 2011 1236 1238
    • (2011) J Clin Oncol , vol.29 , pp. 1236-1238
    • Andre, F.1    Delaloge, S.2    Soria, J.C.3
  • 10
    • 57849117384 scopus 로고    scopus 로고
    • New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    • E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
    • (2009) Eur J Cancer , vol.45 , pp. 228-247
    • Eisenhauer, E.A.1    Therasse, P.2    Bogaerts, J.3
  • 11
    • 0026072872 scopus 로고
    • Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up
    • C.W. Elston, and I.O. Ellis Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 1991 403 410
    • (1991) Histopathology , vol.19 , pp. 403-410
    • Elston, C.W.1    Ellis, I.O.2
  • 12
    • 33847147313 scopus 로고    scopus 로고
    • American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
    • A.C. Wolff, M.E. Hammond, and J.N. Schwartz American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 2007 118 145
    • (2007) J Clin Oncol , vol.25 , pp. 118-145
    • Wolff, A.C.1    Hammond, M.E.2    Schwartz, J.N.3
  • 13
    • 33645341566 scopus 로고    scopus 로고
    • Joint analysis of DNA copy numbers and gene expression levels
    • D. Lipson, A. Ben-Dor, and E.Z.Y. Dehan Joint analysis of DNA copy numbers and gene expression levels Algorithms Bioinform 3240 2004 135
    • (2004) Algorithms Bioinform , vol.3240 , pp. 135
    • Lipson, D.1    Ben-Dor, A.2    Dehan, E.Z.Y.3
  • 14
    • 0033756274 scopus 로고    scopus 로고
    • Comparative genomic hybridization of fine needle aspirates from breast carcinomas
    • N.G. Burki, R. Caduff, and H. Walt Comparative genomic hybridization of fine needle aspirates from breast carcinomas Int J Cancer 88 2000 607 613
    • (2000) Int J Cancer , vol.88 , pp. 607-613
    • Burki, N.G.1    Caduff, R.2    Walt, H.3
  • 15
    • 0035810148 scopus 로고    scopus 로고
    • Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
    • H. Joensuu, P.J. Roberts, and M. Sarlomo-Rikala Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor N Engl J Med 344 2001 1052 1056
    • (2001) N Engl J Med , vol.344 , pp. 1052-1056
    • Joensuu, H.1    Roberts, P.J.2    Sarlomo-Rikala, M.3
  • 16
    • 0035869407 scopus 로고    scopus 로고
    • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    • D.J. Slamon, B. Leyland-Jones, and S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
    • (2001) N Engl J Med , vol.344 , pp. 783-792
    • Slamon, D.J.1    Leyland-Jones, B.2    Shak, S.3
  • 17
    • 33845886440 scopus 로고    scopus 로고
    • Lapatinib plus capecitabine for HER2-positive advanced breast cancer
    • C.E. Geyer, J. Forster, and D. Lindquist Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2006 2733 2743
    • (2006) N Engl J Med , vol.355 , pp. 2733-2743
    • Geyer, C.E.1    Forster, J.2    Lindquist, D.3
  • 18
    • 78049425319 scopus 로고    scopus 로고
    • Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
    • E.L. Kwak, Y.J. Bang, and D.R. Camidge Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 2010 1693 1703
    • (2010) N Engl J Med , vol.363 , pp. 1693-1703
    • Kwak, E.L.1    Bang, Y.J.2    Camidge, D.R.3
  • 19
    • 79959795786 scopus 로고    scopus 로고
    • Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    • P.B. Chapman, A. Hauschild, and C. Robert Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
    • (2011) N Engl J Med , vol.364 , pp. 2507-2516
    • Chapman, P.B.1    Hauschild, A.2    Robert, C.3
  • 20
    • 59449094654 scopus 로고    scopus 로고
    • Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array
    • F. Andre, B. Job, and P. Dessen Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array Clin Cancer Res 15 2009 441 451
    • (2009) Clin Cancer Res , vol.15 , pp. 441-451
    • Andre, F.1    Job, B.2    Dessen, P.3
  • 21
    • 79957857433 scopus 로고    scopus 로고
    • The BATTLE Trial: Personalizing therapy for lung cancer
    • E.S. Kim, R.S. Herbst, and I. Wistuba The BATTLE Trial: personalizing therapy for lung cancer Cancer Discov 1 2011 44 53
    • (2011) Cancer Discov , vol.1 , pp. 44-53
    • Kim, E.S.1    Herbst, R.S.2    Wistuba, I.3
  • 22
    • 79951906119 scopus 로고    scopus 로고
    • Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers
    • D.D. Von Hoff, J.J. Stephenson Jr., and P. Rosen Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers J Clin Oncol 28 2010 4877 4883
    • (2010) J Clin Oncol , vol.28 , pp. 4877-4883
    • Von Hoff, D.D.1    Stephenson, Jr.J.J.2    Rosen, P.3
  • 23
    • 0033031878 scopus 로고    scopus 로고
    • Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization
    • H. Bissig, J. Richter, and R. Desper Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization Am J Pathol 155 1999 267 274
    • (1999) Am J Pathol , vol.155 , pp. 267-274
    • Bissig, H.1    Richter, J.2    Desper, R.3
  • 24
    • 70349706155 scopus 로고    scopus 로고
    • Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites
    • C. Gomez-Roca, C.M. Raynaud, and F. Penault-Llorca Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites J Thorac Oncol 4 2009 1212 1220
    • (2009) J Thorac Oncol , vol.4 , pp. 1212-1220
    • Gomez-Roca, C.1    Raynaud, C.M.2    Penault-Llorca, F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.